Here’s a bold statement: What if aging, often blamed for increasing cancer risk, actually holds the key to suppressing it? A groundbreaking study by Stanford University researchers has flipped the script on our understanding of cancer and age. But here's where it gets controversial: Older laboratory mice, contrary to expectations, develop significantly fewer and less aggressive lung tumors compared to their younger counterparts. This finding challenges the long-held belief that cancer risk invariably rises with age, yet it aligns with observations in very elderly humans, where cancer incidence appears to plateau or even decline.
"It’s a striking finding," remarked Monte Winslow, PhD, associate professor of genetics and pathology. "We’d assume older animals would face more severe cancers, but the data tells a different story. This raises a critical question: What molecular changes tied to aging are secretly working to suppress cancer?"
Despite this intriguing possibility, studying this phenomenon in the lab has been notoriously difficult. With limited data, it’s been nearly impossible to determine how a cancer patient’s age might influence their response to treatments. And this is the part most people miss: Most cancer studies in mice focus on younger animals, overlooking the systemic changes that come with aging.
"Aging transforms the body in ways we’re only beginning to understand," explained Emily Shuldiner, PhD, lead author of the study published in Nature Aging. "When we introduced identical lung cancer-causing mutations in young and old mice, the younger mice developed more aggressive, faster-growing tumors."
Shuldiner’s research, co-led by Winslow and professor of biology Dmitri Petrov, PhD, highlights a critical gap in cancer research. The intuitive assumption that cancer risk climbs with age holds true for most of our lives—cancer rates spike around age 50 and peak between 70 and 80. But after 85, the curve flattens or even drops. Is this due to reduced screening and diagnosis, or is there a deeper biological mechanism at play? Perhaps those predisposed to longevity also have immune systems better equipped to fend off cancer?
The mouse study suggests the latter. "The standard cancer model assumes mutations accumulate with age, eventually triggering cancer," Petrov noted. "But our findings indicate that after a certain age, aging itself may act as a generic form of cancer suppression. It’s a paradigm shift."
Aging brings other genetic changes too: altered DNA methylation patterns, increased genomic instability, and the duplication of DNA segments. Amid this chaos, some changes appear to hinder cancer development—a potential goldmine for new therapies. However, identifying these mechanisms in animals is painstakingly slow.
Shuldiner tackled this challenge head-on. Her mice were genetically engineered to develop fluorescently tagged lung cancers when exposed to an inhaled gene delivery system. To compare tumor formation in young (4–6 months) and old (20–21 months) mice, she waited nearly two years for the animals to age—a testament to her dedication. Once the mice were sufficiently aged, she induced lung cancer. Fifteen weeks later, the results were startling: Young mice had three times more cancer by lung weight and fluorescent imaging, with significantly larger tumors.
"Across every metric, younger mice fared worse," Shuldiner observed.
She then explored the impact of inactivating 25 tumor-suppressor genes—proteins that normally block cancer development—in both young and old mice. While tumor incidence rose in all mice with inactivated genes, the effect was far more pronounced in younger animals. One gene, PTEN, stood out: its inactivation had a dramatically stronger impact in young mice.
"This suggests that the effect of mutations or targeted therapies might differ significantly between young and old patients," Shuldiner explained. She further analyzed gene expression patterns in cancer cells from old mice with active or inactive PTEN. Remarkably, aging signatures persisted in rapidly dividing cancer cells from old mice—unless PTEN was inactivated, in which case the cells resembled those from young animals.
This study is the first to conclusively demonstrate that aging suppresses tumor initiation and growth, alters the impact of tumor suppressor gene inactivation, and preserves aging signatures even in rapidly dividing cancer cells. It underscores the need for new cellular and animal models that account for aging to develop effective therapies.
"Our animal models aim to inform treatments, but they must accurately reflect aging-related changes," Winslow emphasized. Petrov added, "The implications are enormous. Aging might have a beneficial side we can harness for better therapies."
Here’s the thought-provoking question: If aging can suppress cancer, could we one day leverage these mechanisms to create revolutionary treatments? Or are we overlooking other factors that complicate this relationship? Share your thoughts in the comments—let’s spark a discussion!
